Stamulumab

Drug Profile

Stamulumab

Alternative Names: Anti-GDF-8 antibody; Anti-myostatin antibody; MYO 29; MYO-029

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Wyeth
  • Class Monoclonal antibodies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Muscular atrophy; Muscular dystrophies

Most Recent Events

  • 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune
  • 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
  • 07 Feb 2005 Phase-I/II clinical trials in Muscular dystrophy in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top